Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes (Q43068334)

From Wikidata

Jump to navigation Jump to search

scientific article published on 8 May 2010

Language	Label	Description	Also known as
English	Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes	scientific article published on 8 May 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

12

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

7

object named as

Jacek Jassem

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

Gabriel N Hortobagyi

1

object named as

Gabriel N Hortobagyi

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

6

object named as

Valorie F Chan

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

Guillermo L Lerzo

8

object named as

Guillermo L Lerzo

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

Fernando Hurtado de Mendoza

10

object named as

Fernando Hurtado de Mendoza

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

5

object named as

Luis E Fein

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

13

object named as

Ronald A Peck

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

author name string

Henry L Gomez

2

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

Rubi K Li

3

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

Hyun-Cheol Chung

4

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

Xavier B Pivot

9

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

Binghe Xu

11

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

Pralay Mukhopadhyay

14

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

Henri H Roché

15

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

language of work or name

0 references

publication date

8 May 2010

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

122

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

409-418

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

https://scigraph.springernature.com/pub.10.1007/s10549-010-0901-4

0 references

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Adjuvant docetaxel for node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Gr

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Molecular mechanisms of drug resistance

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer?

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Facts and controversies in systemic treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR).

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Assessing the measure of a new drug: is survival the only thing that matters?

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Targeted therapies for the treatment of breast cancer in the post-trastuzumab era.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Is breast cancer survival improving?

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Single agent versus combination chemotherapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Endpoints for assessing drug activity in clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Identifiers

10.1007/S10549-010-0901-4

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43068334&oldid=2119133489"